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Summary: The carboxyterminal propeptide of type 1 procollagen is a biochemical marker of type I collagen synthe-
sis. We evaluated circulating carboxyterminal propeptide of type I procollagen levels in patients with terminal renal
failure before and after kidney transplantation. Serum carboxyterminal propeptide of type I procollagen, osteocalcin,
total alkaline phosphatase, intact parathyrin, creatinine, calcium and phosphate levels were determined in 20 pa-
tients, before and 15, 30, 90 and 180 days after surgery. Serum creatinine and intact parathyrin concentrations
showed a significant decrease after kidney transplantation. Immunosuppressive treatment consisted of low dose
prednisone, cyclosporin and antilymphoblast globulin.
In our group, only 5 patients (25%) showed serum carboxyterminal propeptide of type I procollagen levels higher
than normal before kidney transplantation. At 15 and 30 days, carboxyterminal propeptide of type I procollagen
concentrations showed a decrease, while at 90 and 180 days there was a significant increase above the normal range
(p = 0.006; ANOVA). Serum osteocalcin and total alkaline phosphatase levels increased significantly at the same
time. We found a significant correlation between carboxyterminal propeptide of type I procollagen and osteocalcin
at 15 and 30 days after kidney transplantation. We conclude that the significant increase in carboxyterminal propep-
tide of type I procollagen levels after kidney transplantation reflect an increase in bone turnover. The low doses of
steroids employed do not seem to have a significant inhibitory effect on collagen synthesis.
Introduction
The carboxyterminal propeptide of type I procollagen is
the main protein secreted by the osteoblast, and it arises
from the cleavage of a large precursor of type I collagen
by a specific proteolytic enzyme (1). It is found in the free
form in blood where its concentration is considered to re-
flect the rate of type I collagen synthesis, and it is there-
fore considered to be a marker of bone formation (2).
In rats, it has been shown that carboxyterminal propep-
tide of type I procollagen is bound to and internalized
into endothelial cells of the liver by receptor mediated
endocytosis (3). As it is primarily degraded by the liver
we may suppose that its excretion will not be affected
by glomerular retention. The theoretical advantage of
measuring carboxyterminal propeptide of type I procol-
lagen rather than other markers of bone formation like
osteocalcin or total alkaline phosphatäse, is the fact that
carboxyterminal propeptide of type I procollagen is the
major synthetic product of osteoblasts (4). However,
there are other sites of type I collagen synthesis, such as
skin, that contribute to the circulating levels of procolla-
gen peptides (5). Parathyrin and calcitriol seem to affect
collagen synthesis but the results are controversial
(6—8). In patients with chronic renal failure with high
parathyrin levels and a diminished calcitriol production
(9), serum carboxyterminal propeptide of type I procol-
lagen levels may be affected.
It is known that glucocorticoids inhibit the synthesis of
interstitial procollagen, so that their administration will
decrease the carboxyterminal propeptide of type I pro-
collagen concentration in blood (10).
The aim of this study was to follow carboxyterminal
propeptide of type I procollagen secretion in a group of
transplant patients with good renal function throughout
the entire study period, comparing these data with se-
quential serum osteocalcin and total alkaline phospha-
tase levels, and to evaluate the influence of post-
transplant corticosteroid therapy.
Materials and Methods
Subjects
We studied a group of 20 patients (10 males and 10 females, mean
age 42.3 years, range 18—66 years) with chronic renal failure and
affected with varying degrees of secondary hyperparathyroidism,
who received a cadaveric kidney transplantation. None of the pa-
tients had undergone parathyroidectomy, and all of those with pre-
898 Bonnin el al.': Bone markers post «renal transplantation
vious hypcrparalhyroidism received oral supplements of calcilriol
prior to" transplantation. The post transplant immunosuppressive
therapy consisted ofprednisone (0.5 mg/kg X d progressively de-
creased to 0.1 mg/kg X d), as well as cyclosporin A (dose adjusted
by monitoring with monoclonal antibody) and antilymphoblast
globulin on alternate days up to 5 or 6 doses (11).
Blood samples were obtained sequentially prior to transplantation
and 15,30. 90 and 180 days afterwards. We measured serum creati-
nine, calcium, phosphate, total alkaline phosphatase, intact para-
thyrin. osteocalcin and carboxyterminal propeptide of type I pro-
collagen. Liver function was assessed in all patients by determina-
tion of γ-glutamyltransferase and alanine aminotransferase. Pa-
tients with impaired liver function were excluded from the study.
The procedures followed were in accordance with the ethical stan-
dards of our institution's responsible committee.
A n a l y t i c a l methods
Serum concentrations of creatinine, calcium, phosphate and total
alkaline phosphatase were routinely determined in our laboratory
on a BM/Hitachi 717 analyser using Boehringer Mannheim kits.
Serum intact parathyrin was measured by immunoradiometric as-
say (Incstar Corp., Stillwater MM), using the reference interval of
1.1—4.6 pmol/1 as determined in our laboratory (12). Inter-assay
coefficient of variation (CV) was 7.1% and 7.6% at 4.1 and 41.1
pmol/1 respectively.
Serum osteocalcin was determined by immunoradiometric assay
(ELSA-OSTEO, CIS Bio-International, Gif-sur-Yvette, France) by
means of two monoclonal antibodies against human osteocalcin.
The reference interval, as established in our laboratory, was 19.8
± 5.7 (x ± s) ng/1 in men and 18.3 ± 7.5 μg/l in women. No
significant differences were found between sexes (13). The inter-
assay CV was 8.1% at 26.1 μg/l.
Serum carboxyterminal propeptide of type I procollagen was as-
sayed by a radioimmunoassay (Orion Diagnostica, Findland) based
on human carboxyterminal propeptide of type I procollagen. Refer-
ence intervals were 50—170 μg/l and 38—202 μg/I for men and
women respectively (Orion Diagnostica). The intraassay CV was
10.8% at 20.5 μ§/1.
Sta t i s t i c a l analys is
Between and within subject differences were checked by the analy-
sis of variance (ANOVA) for repeated measurements. The values
showed a normal (Gaussian) distribution. Subgroup differences
measured by the Scheffe test were neglected if the overall test was
not significant. Correlation coefficients were obtained from the
non-parametric Spearman rank test. The level of significance was
defined in all tests as ρ < 0.05.
Results
After kidney transplantation, serum creatinine concen-
trations showed a marked decrease of about 75% with
respect to basal values (p = 0.0004; ANOVA); in the
most patients it was below 200 μιποΐ/ΐ at day 180. Prior
to kidney transplantation serum phosphate was signifi-
cantly increased (p = 0.0014; ANOVA); these values
decreased to normal levels after surgery. Serum calcium
remained in the normal range throughout the study
period. Seven patients had basal intact parathyrin in the
normal range, probably due to calcitriol treatment, but
mean overall values were higher than the normal range
(20.5 pmol/1 versus a reference value of 4.6 pmol/1). Af-
ter surgery, a progressive significant decrease in intact
parathyrin levels was observed (p = 0.0001; ANOVA),
although in some patients they did not attain normal val-
ues even at day 180.
Serum total alkaline phosphatase levels remained in the
normal range before kidney transplantation and at 15
and 30 days after surgery; the values rose gradually at
90 and 180 days (p < 0.01).
Serum osteocalcin concentrations were increased to
about eight times the normal values under basal condi-
tions, showed a marked decrease during the first two
weeks after surgery, then increased significantly up to
180 days (p = 0.002; ANOVA).
Prior to kidney transplantation only 5 patients had ele-
vated serum carboxyterminal propeptide of type I pro-
collagen levels (25%), 4 of them with normal intact
parathyrin levels. At 15 and 30 days after surgery car-
boxyterminal propeptide of type I procollagen concen-
trations showed decrease and a significant increase at 90
and 180 days (p = 0.006; ANOVA). Table 1 shows
mean absolute values of the three bone markers studied
through the study period.
No significant correlations were found between carboxy-
terminal propeptide of type I procollagen/parathyrin, car-
boxyterminal propeptide of type I procol lagen/osteocal-
cin and carboxyterminal propeptide of type I procollagen/
total alkaline phosphatase prior to kidney transplantation.
In the follow-up we found a significant correlation only
between carboxyterminal propeptide of type I procolla-
gen and osteocalcin at 15 and 30 days (r = 0.48, p = 0.05
and r = 0.45, p = 0.05 respectively), although all three
markers increased at the same time (fig. 1).
Discussion
Since carboxyterminal propeptide of type I procollagen
is formed in a 1 : 1 stoichiometric ratio to type I colla-
gen molecules, its serum levels are recognized markers
of osteoblastic activity (2). In cross sectional studies on
healthy adults, circulating carboxyterminal propeptide of
type I procollagen concentrations have been found to
Tab. 1 Serum carboxyterminal propeptide of type I procollagen,
osteocalcin and total alkaline phosphatase levels before and after
kidney transplantation.
Basal
1 5 days
30 days
90 days
180 days
Normal range
Carboxyterminal
propeptide
of type 1
procollagen
(MS»)
154.6 ± 94.5
133.4 ±59.8
124.6 ± 43.5
205.0 ± 89
245.0 ± 100
38.0 - 202
Osteocalcin
(μβ/1)
231 ±286
37 ±42
32 ± 30.5
50 ± 34.4
75 ± 42.8
3-33
Total
alkaline
phosphatase
•fokat/l)
1.4 ± 1.1
1.32 ±0.79
1.47 ±0.66
2.01 ± 1.23
2.36 ± 1.46
0.6 - 1.6
Numbers show means ± SD
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correlate with cancellous bone formation rate (14). A
similar correlation has been found in osteoporosis (15)
and renal osteodystrophy (16).
In a metabolic steady state, there is generally a good corre-
lation between serum carboxyterminal propeptide of type
I procollagen levels and other biochemical markers of
bone formation, e. g. total alkaline phosphatase or osteo-
calcin. However each of these reflects different metabolic
pathways of the osteoblast, and each assay has certain
limitations (2). Total alkaline phosphatase is said to be a
less sensitive marker of osteoblastic activity because it is
also produced in other tissues (17). Bone alkaline phos-
phatase, which is the isoenzyme of skeletal origin, may
improve the specificity and sensitivity. It is known that os-
teocalcin may also be released from bone matrix during
bone resorption (18). Serum carboxyterminal propeptide
of type I procollagen concentrations may measure bone
matrix biosynthesis and reflect bone formation more di-
rectly, although other sites can contribute to circulating
levels. The exact distribution of type I collagen between
bones and soft tissues is not known, but the great majority
is believed to be in bones (5).
Patients with long-standing renal failure are affected
with varying degrees of secondary hyperparathyroidism.
Calcitriol treatment reduces parathyrin levels and pre-
vents hypertrophy of the parathyroid glands.
Coen et al. found a significant decrease in serum carboxy-
terminal propeptide of type I procollagen levels in predia-
lysis patients receiving calcitriol (16). These authors also
found a significant correlation between dynamic histo-
morphometric quantities and carboxyterminal propeptide
of type I procollagen serum levels in their patients.
It is known that after a successful renal transplantation se-
rum parathyrin levels decrease and bone lesions tend to
normalize, however the normalization of circulating para-
thyrin is not instantaneous, and variable periods are re-
quired from one patient to another to achieve normal
levels, depending on previous glandular hypertrophy
(19). The immunosuppressive drugs employed after kid-
ney transplantation may influence the recovery of bone
lesions.
In our group prior to transplantation all patients were
receiving calcitriol supplementation. After renal trans-
plantation the patients studied recovered good renal
function but some patients had serum parathyrin concen-
trations above the normal range, even at 180 days.
Prior to surgery, mean serum carboxyterminal propep-
tide of type I procollagen levels were in the normal
range, possibly due to the inhibitory effect of high intact
parathyrin levels or induction by calcitriol treatment. At
15 and 30 days after kidney transplantation, carboxyter-
minal propeptide of type I procollagen levels were also
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Fig. 1 Mean serum carboxyterrninai propeptide of type I procol- levels before and 15, 30, 90 and 180 days after kidney transplanta-
lagen, intact parathyrin, osteocalcin and total alkaline phosphatase tion. Shadowed areas represent references ranges.
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in the normal range but lower than previously: the refer-
ence interval is relatively broad, so that even changes
occurring within the reference interval may be impor-
tant. The higher dose of corticosteroids employed during
this period may be responsible for these changes. The
significant increases in carboxyterminal propeptide of
type I procollagen levels observed at 90 and 180 days
may reflect an increase in osteoblastic activity that is
not affected by the lower dose of corticosteroids used at
this time.
There is no correlation between carboxyterminal pro-
peptide of type I procollagen and parathyrin levels
throughout the study period, in accordance with other
authors (16); this fact suggests that other factors like
calcitriol may be the main regulator of carboxyterminal
propeptide of type I procollagen concentration.
Prior to transplantation we found no correlation be-
tween carboxyterminal propeptide of type I procolla-
gen levels and the other markers of bone formation
studied, in accordance with previous reports (10),
probably due to different functional osteoblastic states.
After kidney transplantation the only significant corre-
lation was that between carboxyterminal propeptide of
type I procollagen and osteocalcin at 15 and 30 days,
but the fact that the three markers increased at the
same time signifies that the three bone formation
markers behave similarly in all the patients. Small
doses of corticosteroids do not seem to decrease circu-
lating levels of the bone markers studied, in contrast
with other studies (10, 20, 21).
We conclude that the significant increase in carboxyter-
minal propeptide of type I procollagen levels at 90 and
180 days, above the reference interval, after kidney
transplantation may reflect an increase in osteoblastic
activity in these patients. The low doses of steroids em-
ployed in our treatment schedule do not seem to have a
significant inhibitory effect on collagen synthesis.
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